Finalist

Empathy, Expertise, and Execution: A Holistic Approach to Launch in Rare Kidney Disease

By Travere Therapeutics
With support from Caudex, an IPG Health Company

Summary of work

The launch of FILSPARI (sparsentan) for IgA nephropathy (IgAN) marks a groundbreaking moment in nephrology, addressing a treatment gap that has persisted for decades. Caudex’s journey with Travere Therapeutics is informed by:

  • Historical perspective and insight: Our understanding of IgAN’s historical treatment landscape combined with current patient and physician insights defined our strategic direction. Our deep understanding enabled us to anticipate challenges and identify key opportunities for FILSPARI.
  • Empathy and patient-centricity: Deep-rooted in our approach was our commitment to genuinely understand the challenges faced by people living with IgAN and their physicians. This foundational empathy shaped our approach to addressing medical needs and empowering the IgAN community.
  • Scientific expertise and targeted communication: Harnessing our robust expertise in IgAN, we prioritised tailoring our messages to meet the needs of each audience. Whether addressing patients, caregivers, or healthcare professionals, we ensured the nuances of FILSPARI’s promise would be conveyed with precision and understanding.

Our medical communications strategy, crafted for the unique challenges of IgAN, emphasized close collaboration with healthcare professionals, and the positive early feedback from nephrologists affirms that approach. Simply put: we listen, we understand, and together, we act to make real impact.

Judges' comments

Travere Therapeutics and Caudex have created a strong campaign that has clearly excited the clinical community in an area that has not seen much attention for a long time. The design, execution and results were all brilliant, and the sentiment scale used to track success in HCPs stood out to the judges.